Piramal Pharma Solutions (PPS), a global leader in contract development and manufacturing (CDMO) and a division of Piramal Pharma Ltd., has announced the installation of a cutting-edge Korsch XM-12 bilayer tablet press at its Morpeth facility in the
The National Institutes of Health (NIH) launched an initiative to advance research on whole person health that aims to create the first integrated knowledge network of healthy physiological function. This initiative takes a health approach...
Eli Lilly and Company announced promising topline findings from its ACHIEVE-3 Phase 3 study, revealing that their investigational GLP-1 receptor agonist, orforglipron, which is administered orally once a day, was associated with better results...
.jpeg "Eli Lilly to Launch Weight-Loss Pill in India Soon")
Eli Lilly is preparing to introduce Orforglipron, its experimental oral weight-loss drug, in India, after the successful launch of its injectable therapy Mounjaro (tirzepatide) earlier this year. According to company executives
Metropolis Healthcare, a diagnostics company with its headquarters in Mumbai, stated on Thursday that it has paid Rs 17 crore to acquire Ambika Pathology Laboratory, located in Kolhapur.A deferred component of Rs 1.7 crore is included in the consider
Sai Life Sciences, a contract research, development, and manufacturing organization (CRDMO) focused on innovative medicines, announced Unit VI inauguration in Bidar, India, to manufacture veterinary active pharmaceutical...
Biocon Biologics Ltd, a fully integrated global biosimilars company and a unit of Biocon Ltd, has obtained the US Food and Drug Administration (FDA) approval for their denosumab biosimilars
Since its injectable medication Stelara, which generated over $10 billion in sales last year, is up against fierce competition from less expensive competitors, J&J has been developing more practical psoriasis treatment choices
.jpg "ICRA sees steady growth ahead for Indian pharma industry")
India's pharmaceutical industry is set to record healthy revenue growth of 7-9 per cent in FY26, even as challenges in the United States market continue to weigh on performance, noted rating agency ICRA in its latest sector outlook
New data from the HS-OBTAIN phase 2a study (NCT05849922) that has been released today at the EADV 2025 Congress in Paris shows that the investigational therapy brivekimig has most significantly improved the region of skin disease in patients with...
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")